Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2019) 63 GP114 | DOI: 10.1530/endoabs.63.GP114

ECE2019 Guided Posters Calcium and Bone 2 (11 abstracts)

Qualitative and quantitative parameters of diabetic osteopathy in type 1 diabetes mellitus

Yuliya Dydyshka 1 , Nadezhda Karytska 2 , Alla Shepelkevich 1 , Natalia Vasilieva 3 & Volga Zhukouskaya 4


1Belarusian State Medical University, Minsk, Belarus; 210th city clinical hospital, Minsk, Belarus; 3Republic Center of Endocrinology and Medical Rehabilitation, Minsk, Belarus; 4Department of Clinical Medicine and Surgery, Division of Endocrinology, University of Naples Federico II, Naples, Italy.


Background and aims: Diabetic osteopathy in patients with type 1 diabetes (T1DM) is obvious. However, approaches to its diagnosis are still ambiguous. Thus, the aim was to study the features of serum osteo-specific parameters and dual energy X–ray absorptiometry (DXA) data in T1DM patients.

Materials and methods: 157 patients with T1DM (105 women, 52 males) (mean age: 32.5 (25.5–41.6) yrs, duration of DM: 13 (7–20) yrs, age of manifestation: 19 (14–23) yrs, BMI: 23.43 (21.55–25,70) kg/m2; HbA1c: 8.2 (7.6–8.9) %) and 98 (67 women, 31 men) controls, comparable in sex, age and anthropometric data. The research involved general clinic examination, serum bone-specific parameters, DXA (bone mineral density (BMD) and trabecular bone score (TBS) of lumbar spine). Z–score of –2.0 or less was regarded as «low bone mineral density».

Results: There were no significant differences in L1-L4 BMD and TBS in women compared with men: 1.16 (1.08–1.26 vs. 1.16 (1.08–1.28) g/sm2; (U=5506; P=0.694) and 1.40 (1.35–1.46) vs. 1.44 (1.37–1.49) (U=3230; P=0.097). Similar results were obtained in subgroups of T1DM patients and controls. There was a definite link between BMD (L1–L4) and TBS (L1–L4) – r2=0.33, P<0.001. Low BMD was detected in 14.6% (23) of the surveyed patients with T1DM and 4.1% (4) of controls. T1DM patients compared to controls had lower BMD and TBS: BMD 1.14 (1.04–1.22) vs 1.23 (1.13–1.33) g/cm2; U=3606; P<0.001; TBS 1.39 (1.33–1.46) vs 1.45 (1.39–1.48); U=2775; P<0.001), T-score TBS −0.30 (−1.90–0.30) vs 0.10 (−1.025–0.90); U=248.5; P=0.018; Z-score TBS −0.30 (0.00–0.50) vs. 0.15 (−0.50–1.00), U=617; P=0.092. In T1DM patients was established decreased alkaline phosphatase (77.98 (67.78–85.18) vs 93.4 (75.58–110.8) U/l; U=698; P<0.001) and osteocalcin (10.58 (8.08–15.70) vs 19.73 (15.16–26.30) ng/ml; U=545; P<0.001) compared with the control group. There were an increased osteoprotegerin levels (4.44 (3.38–5.77) vs 2.74 (2.15–3.54) pmol/l; U=94; P<0.001) and a decreased the RANKL/osteoprotegerin ratio (0.03 (0.02–0.06) vs 0.05 (0.04–0.07), U=155; P=0.017).

Conclusions: T1DM patients have decreased bone formation markers (alkaline phosphatase, osteocalcin) and elevated resorption markers (osteoprotegerin), which can lead to impaired mineralization (low BMD) and microstructure (low TBS).

Volume 63

21st European Congress of Endocrinology

Lyon, France
18 May 2019 - 21 May 2019

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.